High-performance liquid chromatographic determination of rivastigmine in human plasma for application in pharmacokinetic studies

Iranian Journal of Pharmaceutical Research

Volumn 9, Issue 2, 2010, Pages 115-121

  Amini, Hossein ^a,b   Ahmadiani, Abolhassan ^b  

^a GOLESTAN UNIVERSITY   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hplc; Liquid liquis extraction; Pharmacokinetics; Rivastigmine; Spectrophotometric detection

Indexed keywords

CITALOPRAM; DONEPEZIL; NORVERAPAMIL; RIVASTIGMINE; ZOLPIDEM;

ANALYTIC METHOD; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIQUID LIQUID EXTRACTION; LOW DRUG DOSE; NORMAL HUMAN; PLASMA; SINGLE DRUG DOSE;

EID: 77954737375     PISSN: 17350328     EISSN: 17266890     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Polinsky RJ. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of alzheimer's disease. Clin. Ther. (1998) 20: 634-647.
2. Jann MW. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of alzheimer's disease. Pharmacotherapy (2000) 20: 1-12.
3. Hossian M, Jhee SS, Shiovitz T, McDonald C, Sedek G, Pommier F and Cutler NR. Estimation of the absolute bioavailability of rivastigmine in patients with mild to moderate dementia of the alzheimer's type. Clin. Pharmacokinet. (2002) 41: 225-234.
4. Gobburu JV, Tammara V, Lesko L, Jhee SS, Sramek JJ, Cutler NR and Yaun R. Pharmacokinetic-pharmacodynamic modeling of rivastigmine, a cholinesterase inhibitor, in patients with alzheimer's disease. J. Clin. Pharmacol. (2001) 41: 1082-1090.
5. Lee L, Hossain M, Wang Y and Sedek G. Absorption of rivastigmine from different regions of the gastrointestinal tract in humans. J. Clin. Pharmacol. (2004) 44: 599-604.
6. Sha Y, Deng C, Liu Z, Huang T, Yang B and Duan G. Headspace solid-phase microextraction and capillary gas chromatographic-mass spectrometric determination of rivastigmine in canine plasma samples. J. Chromatogr. B (2004) 806: 271-276.
7. Pommier F and Frigola R. Quantitative determination of rivastigmine and its major metabolite in human plasma by liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. J. Chromatogr. B (2003) 784: 301-313.
8. Enz A, Chappuis A and Dattler A. A simple, rapid and sensitive method for simultaneous determination of rivastigmine and its major metabolite NAP 226-90 in rat brain and plasma by reversed-phase liquid chromatography coupled to electrospray ionization mass spectrometry. Biomed. Chromatogr. (2004) 18: 160-166.
9. Frankfort SV, Ouwehand M, van Maanen MJ, Rosing H, Tulner LR and Beijnen JH, A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry. Rapid Commun. Mass Sp. (2006) 20: 3330-3336.
10. Bhatt J, Subbaiah G, Kambli S, Shah B, Nigam S, Patel M, Saxena A, Baliga AK, Parekh H and Yadav G. A rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method for the estimation of rivastigmine in human plasma. J. Chromatogr. B (2007) 852: 115-121.
11. Karthik A, Subramanian GS, Surulivelrajan M, Ranjithkumar A and Kamat SB. Fluorimetric determination of rivastigmine in rat plasma by a reversed-phase high performance liquid chromatographic method. Application to a pharmacokinetic study. Arzneimittelforschung (2008) 58: 205-10.
12. Rao BM, Srinivasu MK, Kumar KP, Bhradwaj N, Ravi R, Mohakhud PK, Reddy GO and Kumar PR. A stability indicating LC method for rivastigmine hydrogen tartrate. J. Pharm. Biomed. Anal. (2005) 37: 57-63.